Nobivac® Parvo-C lyophilisate for suspension for injection for dogs
Nobivac Parvo-C is most often used in puppies to provide additional immunisation in animals at high risk of early exposure to canine parvovirus from as early as 4 weeks of age.
Presentation
Lyophilisate for suspension for injection
Active ingredients
Nobivac Parvo-C contains live, attenuated, freeze dried canine parvovirus.
Per dose of 1 ml:
Live canine parvovirus (CPV), strain 154 ≥ 107.0 TCID50*
*Tissue Culture Infective Dose 50%
Target species
Dogs
Indications for use
Nobivac Parvo-C is indicated for active immunisation of dogs to prevent mortality, clinical signs and viral excretion following canine parvovirus infection.
Specific claims: An onset of immunity to the canine parvovirus vaccine component of 1 week has been demonstrated following use of the vaccine. A duration of immunity of at least three years has been established for the canine parvovirus vaccine component.
Packaging
A plastic box containing 10 vials
Legal category
POM-V
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Product images are representations of packaging and may not accurately reflect the current packaging available in the GB marketplace.
Date of preparation: July 2025